Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Serum Laboratory Studies, Stool Test, Breath Test

Serum Laboratory Studies, Stool Test, Breath Test

Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026

Same author

Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.

Cancer cell·2026

Same author

Enhanced dynamic risk stratification of smoldering multiple myeloma.

Nature medicine·2026

Same author

ATOMIC Energy - Biomarker-Bespoke Adjuvant Therapy for Colon Cancer.

The New England journal of medicine·2026

Same author

Obesity Accelerates Multiple Myeloma Progression in Certain Mouse Models and in Humans.

Cancer prevention research (Philadelphia, Pa.)·2026

Same author

Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results.

Cancer research communications·2026

Search research articles

Related Experiment Video

Updated: Jul 14, 2025

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study.

Deb Schrag¹, Tomasz M Beer², Charles H McDonnell³

¹Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Lancet (London, England)

|October 7, 2023

Summary

Multicancer early detection (MCED) blood tests show promise for cancer screening. The PATHFINDER study demonstrated the feasibility of MCED testing, with results guiding diagnostic assessments for participants with a detected cancer signal.

More Related Videos

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

Related Experiment Videos

Last Updated: Jul 14, 2025

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

Area of Science:

Oncology
Genomics
Clinical Trials

Background:

Multicancer early detection (MCED) blood tests analyze circulating cell-free DNA (cfDNA) to detect cancer signals.
The PATHFINDER study was designed to assess the feasibility of using MCED tests for cancer screening in a real-world setting.

Purpose of the Study:

To investigate the feasibility of multicancer early detection (MCED) blood testing for cancer screening.
To evaluate the diagnostic pathway and time to resolution following a positive MCED test result.

Main Methods:

A prospective cohort study involving adults aged 50+ without cancer symptoms across seven US health networks.
Participants underwent MCED blood testing; positive results, indicating a cancer signal, guided subsequent diagnostic evaluations.
Circulating cell-free DNA (cfDNA) methylation signatures were analyzed to predict cancer signal origin.

Main Results:

A cancer signal was detected in 1.4% of 6621 participants with analysable results.
Of those with a detected signal, 38% were diagnosed with cancer (true positives) and 62% were not (false positives).
Median time to diagnostic resolution was 79 days, with fewer procedures and surgeries in false-positive cases compared to true positives.

Conclusions:

The study supports the feasibility of implementing multicancer early detection (MCED) blood tests in cancer screening protocols.
Further research is warranted to fully establish the clinical utility and impact of MCED testing on patient outcomes.